In the early stages, scientists from the St. Petersburg Institute of Nuclear Physics, together with colleagues from the First St. Petersburg State Medical University, have developed a new drug to combat Parkinson's disease in the early stages. It affects the enzyme glucocerebrosidase, whose insufficient functioning is associated with an increased risk of developing the disease. Discuss© Ferra
Scientists have developed a molecule that can restore the activity of this enzyme, which helps prevent accumulation of harmful substances in cells causing neuronal degeneration. When creating the drug, scientists used the results of research by foreign colleagues who developed a pharmacological chaperone capable of restoring the functioning of protein formations.
Experiments showed that the new drug more effectively reduces the amount of harmful substances than foreign analogues that are already on the market. stage of clinical trials.
News materials cannot be equated to a doctor’s prescription. Before making a decision, consult with a specialist.